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Abstract 
Aim of the study 
Aim of the study was the development of ζ potential changing nanoparticles as gene delivery 
system for the cystic fibrosis transmembrane conductance regulator gene. Methods 
Chitosan and carboxymethyl cellulose were modified with phosphotyrosine, a substrate for 
the brush border enzyme alkaline phosphatase. With these synthesized derivatives, different 
nanoparticle formulations, including the cystic fibrosis transmembrane conductance regulator 
gene were prepared by ionic gelation. 
Results 
A change from negative to positive ζ potential after enzymatic cleavage could be observed. 
Transfection studies with HEK-293 and Caco-2 cells showed transfection rates comparable to 
Lipofectamine 2000. Transfection efficiencies were significantly decreased when phosphate 
cleavage and thus ζ potential change was inhibited by phosphatase inhibitor.  
Conclusion 
The developed nanoparticles represent a promising gene delivery system. 
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1. Introduction 
With ever-growing interest in gene therapy, the demand for efficient gene delivery systems 
increases rapidly. The introduction of gene therapeutics into cells allows for the replacement 
of defect or missing genes and hence the expression of certain proteins. Because of their high 
selectivity and target-specificity they are supposed to show a higher efficiency and less side 
effects compared to conventional drugs [1]. However, efficient gene delivery still remains a 
major challenge in pharmaceutical technology as low cellular uptake, enzymatic DNA-
degradation and the mucosal barrier require efficient gene delivery systems, especially in case 
of mucosal drug delivery. As viral vectors show high immunogenicity, research concentrated 
on non-viral delivery systems in the last years. Most systems consist of cationic polymers and 
lipids [1,2] as they easily form complexes with DNA and it has been shown that positively 
charged nanoparticles show a higher rate of cell uptake than negatively charged ones [3-5]. 
However, most epithelial cells are covered by the mucus gel layer, which, due to its negative 
net charge immobilizes positive particles before they reach the epithelium. In contrast, 
negatively charged nanoparticles diffuse significantly faster in mucus [6]. Recent studies have 
shown that ζ potential changing nanoparticles can combine these two desirable but contrary 
properties of positive and negative ζ potential7 [7-10].  These nanoparticles bear negatively 
charged functional groups that are substrates for brush border enzymes. Once the 
nanoparticles have crossed the mucus layer, these functional groups will be cleaved off 
enzymatically, changing the ζ potential of the particles. Thus, they are immobilized and can be 
preferably endocytosed by epithelial cells. For this study, phosphotyrosine, a substrate for 
intestinal alkaline phosphatase (IAP),  was chosen as functional group and conjugated with 
each chitosan and carboxymethyl cellulose as described before [7]. The modified polymers 
were then used to prepare nanoparticles containing pDNA. The pDNA chosen for the present 
6 
 
study includes a CFTR gene, which encodes for the cystic fibrosis transmembrane conductance 
regulator, an ion channel that transports chloride ions from the cell interior to the mucus gel 
layer, keeping the osmotic homeostasis. Genetic defects in the CFTR gene cause dysregulation 
of the fluid transport across the epithelium, thus leading to mucus thickening mainly in the 
respiratory and gastrointestinal tract and resulting in cystic fibrosis (CF). To date, cystic 
fibrosis, the most common life-threatening autosomal recessive disease among Caucasians 
with an incidence of 1 in 2500 [11-13], is mainly treated symptomatically. The only causal 
treatments are Ivacaftor (licensed in 2012), which is targeting a specific mutation related to 
approximately 5% of CF patients [13], and Lumacaftor in combination with Ivacaftor. On the 
contrary, CFTR gene therapy could be used for causal treatment of CF patients regardless of 
the mutation [13-15]. 
The pDNA containing nanoparticles were investigated regarding their suitability as gene 
delivery systems, using cultured epithelial cells as a model system. Therefore, the ζ potential 
and the change of the ζ potential after enzymatic cleavage was investigated. HEK-293 and 
Caco-2 cells were used to evaluate the cytotoxic potential of the nanoparticles and the 
phosphate cleavage by the monolayers. Moreover, the transfection efficiency of the 
nanoparticles was evaluated with both cell lines. The protective effect of the nanoparticles 
against enzymatic degradation of the pDNA by DNase I was investigated using gel 
electrophoresis.  
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2. Materials and methods 
2.1. Materials 
Phosphotyrosine was purchased from Bachem Holding AG, Bubendorf, Switzerland. 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride was obtained from Acros, 
Geel, Belgium. Midori Green Advance was obtained from Biozym Biotech Trading GmbH, 
Vienna, Austria. Nuclease-free, DEPC treated water was purchased from LACTAN GmbH, Graz, 
Austria. EndoFree® plasmid purification kit was obtained from Qiagen, Hilden, Germany. 
Lipofectamine® 2000 Transfection Reagent and  goat serum (10%) were purchased from Fisher 
Scientific - Austria GmbH, Vienna, Austria. Rabbit monoclonal to alkaline phosphatase, tissue 
non-specific and goat anti-rabbit IgG H&L; Alexa Fluor® were purchased from Abcam, United 
Kingdom. Cell culture microplates were purchased from Greiner Bio-One GmbH, 
Kremsmünster, Austria. All other cell culture supplies were purchased at Biochrom GmbH, 
Berlin, Germany. Chitosan (20 kDA) was purchased from Heppe Medical Chitosan GmbH, 
Germany. Carboxmethyl cellulose (90 kDa), alkaline phosphatase from bovine intestinal 
mucosa, phosphatase inhibitor cocktail 2 and all other substances were purchased from 
Sigma-Aldrich Handels GmbH, Vienna, Austria. 
2.2. Polymer synthesis & characterization 
Phosphotyrosine (PTyr) was conjugated to each chitosan (CS) and carboxymethyl cellulose 
(CMC) in carbodiimide-catalyzed reactions as described previously [7]. For the synthesis of the 
phosphotyrosine-bearing chitosan derivative (CS-PTyr), 1 g of 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC) was added to 50 mL of 
an aqueous solution of 250 mg phosphotyrosine and 500 mg chitosan (20 kDA) and the pH 
was adjusted to 5. After an overnight reaction at 40 °C the mixture was purified from unbound 
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PTyr and EDAC by dialysis for 3 days against 12 L of demineralized water using Zellutrans/Roth 
dialysis membrane (MWCO 3500 Da). The dialysis medium was exchanged every 12h. The 
purified product was lyophilized using a Gamma 1-16 LSC (Christ, Osterode, Germany) and 
stored dry at 8 °C.  
In a similar manner, phosphotyrosine was conjugated with CMC. 1 g of CMC (90kDa) in 50 mL 
demineralized water was activated by addition of 2 g EDAC at a pH of 5. After an incubation 
time of 15 min, 500 mg of PTyr was added and the mixture was stirred over night at 40 °C. The 
synthesized polymer was purified as described above using Nadir® cellulose membrane 
(MWCO 10-20 kDa), lyophilized and stored at 8 °C. As controls, the syntheses were performed 
without EDAC. 
The amount of conjugated PTyr was quantified spectrophotometrically. Samples of the 
synthesized derivatives were dissolved in 0.5 M HCl (CS-PTyr) or 20 mM TRIS buffer (pH 8.5) 
(CMC-PTyr), respectively, and the absorbance at 265 nm was determined. The amount of 
conjugated PTyr was then calculated using a calibration curve of PTyr standards. 
2.3. Preparation of the plasmid 
CFTR DNA subcloned into the pIRES2-EGFP vector (Clontech, Palo Alto, CA, USA) as described 
by Gong et al. [16] was a gift from Prof. Paul Linsdell. pIRES-EGFP-CFTR plasmid DNA was 
amplified in E. coli cells and purified using an EndoFree® Plasmid Purification Kit from Qiagen. 
After purification, the plasmid was dissolved in nuclease free water and quantified with a 
NanoDrop 2000c UV-Vis Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). 
Aliquots were stored at -20 °C until further use. 
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2.4. Nanoparticle preparation & characterization 
Nanoparticles were prepared by ionic gelation utilizing the opposite charges of the CS-PTyr 
and the pDNA and accordingly the CMC-Ptyr. The formulations were composed of either 
CS-PTyr with pDNA or CS-Tyr with pDNA and CMC-PTyr, respectively. Therefore, 0.1% (m/v) 
stock solutions of both polymers dissolved in 25 mM sodium acetate were prepared and pH 
was adjusted to 6.8. These solutions were sterile filtered through 0.2 µm filters. Aliquots of 
the polymer solutions and the pDNA solution were heated separately to 55 °C. CS-PTyr was 
then diluted in preheated nuclease free water and mixed with either pDNA or pDNA and 
CMC-PTyr. Each mixture was vortexed immediately for 20 s. Different formulations were 
prepared and compositions of the different formulations are given in Table 1. 
The ζ potential of these nanoparticles was measured using a Nicomp™ 380 ZLS (Santa Barbara, 
CA, USA) with a laser wavelength of 632.8 nm and the E-Field Strength set to 5 V/cm. To 
determine the change of ζ potential after enzymatic cleavage it was measured before and 
after addition of two units of IAP. 
2.5. Encapsulation efficiency  
The encapsulation efficiency of the pDNA in the nanoparticles was determined within a gel 
electrophoresis study. Nanoparticles were prepared as described above and investigated by 
gel electrophoresis using a HE 33 mini submarine electrophoresis unit (Hoefer, Inc., San 
Francisco, CA, USA). Naked pDNA served as control. An 1% agarose gel was prestained with 
Midori Green Advance DNA stain (Biozym Biotech Trading GmbH, Vienna, Austria) and DNA 
bands were detected under UV-light. 
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2.6. Cytotoxicity 
To detect cytotoxic effects of the polymers and nanoparticles on HEK-293 and Caco-2 cells a 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay was performed 
[17]. Viable cells reduce MTT to insoluble formazan crystals, which can be quantified 
spectrophotometrically once redissolved in DMSO. Therefore, the HEK-293 and Caco-2 cells, 
respectively, were each seeded in 96-well plates at a concentration of 2 x 105 cells/mL of MEM 
(minimum essential medium, containing 10% fetal bovine serum and antibiotics). Cells were 
then incubated for 24 h at 37 °C and 5 % CO2 and afterwards washed twice with phosphate 
buffered saline (PBS). Subsequently, 100 µl of the samples with corresponding final pDNA 
concentrations of 5 – 20 µg/mL were applied. Pure MEM and Triton x® 100 4 % (v/v) were 
applied as negative and positive controls. The cells were incubated for 4.5 hours under 
abovementioned conditions before discarding the supernatant and washing the cells twice 
with PBS. To detect the amount of viable cells 100 µl of a 0.5% (m/v) MTT solution in MEM 
was added and incubated for 4.5 hours before removing the supernatant. The precipitated 
formazan crystals were dissolved in 100 µl of DMSO and the absorbance of the formazan 
solutions was measured at a wavelength of 570 nm with a reference wavelength of 690 nm 
using a microplate reader (Tecan infinite, M200 spectrometer, Grödig, Austria). The 
cell-viability was calculated as percentage of the negative control. 
2.7. Enzymatic phosphate cleavage by HEK-293 & Caco-2 monolayers 
The enzymatic cleavage of phosphate off the nanoparticles by HEK-293 and Caco-2 
monolayers was investigated. Cells were seeded in 24-well plates in a concentration of 2 x 105 
cells/mL. After incubating for 24 h, cells were washed twice with a solution consisting of 268 
mM glucose and 27 mM HEPES (pH 7.4) before adding 500 µl of the nanoparticle suspensions. 
These were added with and without the presence of phosphatase inhibitor cocktail 2 (1 % v/v). 
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The cells were then incubated at 37 °C and 5 % CO2. Samples of 50 µl were taken at 
predetermined time points and the enzymatic reaction was terminated immediately by adding 
5 µl of H2SO4 (3.6 M). The amount of cleaved phosphate was quantified utilizing the malachite 
green assay as described previously [8]. 100 µl of malachite green reagent (6 mL of a 7.5% 
ammonium molybdate solution + 10 mL of a 0.15% malachite green solution in sulfuric acid 
(3.6 M) + 0.4 mL of a 11% Triton-X 100 solution) were added to each sample and the 
absorbance at a wavelength of 630 nm was measured. The amount of released phosphate was 
calculated using a calibration curve of phosphate standards. 
In order to confirm that the cell lines contain the alkaline phosphatase, immunocytochemistry 
images were taken from the stained metallo-enzyme alkaline phosphatase (AP) in Caco-2 and 
HEK293 cells according to the vendor protocol (Abcam; UK). Both cell lines were cultured on 
a 96 well plate in a density of 2*105 cells/ml in 100 l of minimum essential medium (MEM) 
for 24 h at 37 °C and 5% CO2. First, the cells were fixed with 100 l of pure methanol and 
incubated for 5 min at room temperature. In order to obtain permeable cells, 100 l 0.1% 
(m/m) Triton X-100 diluted in phosphate buffer saline (PBS) buffer pH 7.4 were added and 
incubated for 5 min at room temperature. Thereafter, cells were treated with 50 l normal 
goat serum (10%) (Fisher Scientific, UK) for 1 h at 4°C to block the unspecific interactions. In 
addition, half of the cell vials were incubated with 50 µl primary antibody to AP (Rabbit 
monoclonal to alkaline phosphatase, tissue non-specific; Abcam; UK) in a concentration of 
4.88 µg/ml as positive control (stored in PBS buffer containing 0.01% (m/m) sodium azide, 
50% (m/m) glycerol and 0.05% (m/m) bovine serum albumin). In contrast, the other half was 
treated with 50 µl PBS buffer pH 7.4 as negative control. The plate was then incubated at 4°C 
for 12 h. After three washing steps with PBS buffer, 50 µl of secondary antibody (Goat anti-
rabbit IgG H&L; Alexa Fluor®) in a concentration on 2 µg/ml (stored in PBS buffer containing 
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0.02% (m/m) sodium azide, 30% (m/m) glycerol and 1% (m/m) bovine serum albumin) were 
applied to all cells and incubated for 1 h at 4°C. Thereafter, all cells were once again washed 
for three times washed with PBS buffer. Furthermore, between all experimental steps PBS 
buffer pH 7.4 was utilized as washing buffer. Images were taken with a combination of a 
microscope (Motic Type AE31, Motic GmbH, Germany) and a camera (ProgRes, Jenoptik, 
Germany) utilizing ProgRes CapturePro software (Jenoptik, Germany) to visualize 
fluorescence. 
2.8. Transfection studies 
Transfection studies were performed with HEK-293 and Caco-2 cells. Cells were seeded in 
24-well plates in a concentration of 4 x 105 cells per mL and incubated for 48 h to gain 
approximately 90 % confluency prior to transfection. The nanoparticle formulations NP-CS 1 
and NP-CMC-CS, prepared as described above were diluted with OPTI MEM® reduced serum 
medium without antibiotics to a final concentration of 5 µg pDNA/mL. Each well was loaded 
with 500 µL of the samples. As control, wells were loaded with samples containing the 
nanoparticles and the phosphatase inhibitor as well as samples containing naked DNA and 
pDNA-Lipofectamine® 2000 complex, respectively. The pDNA-Lipofectamine complex was 
prepared according to the instructions of the manufacturer in a ratio of 1:2 
(DNA:Lipofectamine™ 2000) and showed a ζ potential of 14.7 ± 1.42 and a size of 
190.65 ± 92.09. The pDNA concentration applied to the cells corresponded to that of the 
nanoparticle formulations. After an incubation time of 4.5 h the supernatant was discarded 
and 500 µl of MEM with FCS and antibiotics was added. After 48 h, the supernatant was 
discarded and cells were harvested for the GFP assay [18]. 
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2.9. Green fluorescence protein assay 
The transfection efficiency was determined by a GFP assay as described previously [18]. The 
cells were washed twice with pre-warmed PBS before lysing them with 100 µl of PBS 
containing 0.2 % Triton X-100 and 1 mM dithiothreitol, followed by a freeze-thaw cycle. 
Afterwards, 50 µl of each lysate was transferred to a 96-well fluorescence plate to determine 
the amount of GFP by measuring the fluorescence at an excitation wavelength of 488 nm and 
an emission wavelength of 510 nm with a microplate reader (Tecan infinite, M200 
spectrometer, Grödig, Austria). 
2.10. Statistical data analysis 
GraphPad Prism® 5 was used for statistical data analysis. One-way ANOVA with Bonferroni 
post test was performed. Mean values were calculated from at least three independent 
samples, respectively. 
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3. Results 
3.1. Characterization of polymers & nanoparticles 
The synthesis of CS-PTyr and CMC-PTyr and the formation of the nanoparticles is shown 
schematically in Figure 1.  The derivatization of the polymers was accomplished by a covalent 
amide bond formation catalyzed by EDAC. In the case of CS-PTyr, the bond was formed 
between the amino group of the CS and the carboxyl group of PTyr while with CMC-PTyr it 
was established between the carboxyl group of the CMC and the amino group of PTyr. The 
amount of conjugated PTyr was determined by spectrophotometric analysis, showing 
coupling rates of 862.34 ± 30.68 µmol/g chitosan (0.139 PTyr subunits / monomer subunit CS) 
and 258.54 ± 12.92 µmol/g CMC (0.062 PTyr subunits / monomer subunit CMC). The control 
syntheses without EDAC showed only negligible amounts of PTyr.  
3.2. Nanoparticles 
The derivatized polymers and the pDNA were used to prepare nanoparticles via ionic gelation. 
The nanoparticles formed spontaneously after mixing due to the ionic interactions of CS-PTyr 
with pDNA and CMC-PTyr. Different formulations were prepared, consisting of either CS-PTyr 
and pDNA in different ratios (#1-3) or CS-PTyr and both pDNA and CMC-PTyr (#4). The ζ 
potential of these formulations before and after incubation with IAP was investigated by 
electrophoretic light scattering. As illustrated in Figure 2, a ζ potential change after enzymatic 
cleavage was measured in all tested formulations. A ζ potential change from negative to 
positive was observed for the formulations #1 and #4. Thus, these two formulations were 
selected for further investigations. 
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3.3. Encapsulation efficiency  
The successful encapsulation of the pDNA into the nanoparticles was verified via gel 
electrophoresis showing a strong fluorescence signal of stained pDNA on the bottom of the 
application pocket in case of nanoparticles being unable to permeate into the gel. Merely in 
case of formulation #1 a minor amount of pDNA was obviously leaking out of the nanoparticles 
migrating into the gel. In contrast, naked pDNA moved in the gel showing bands being 
characteristic for a plasmid (Figure 3). 
3.4. Cytotoxic effects 
Cell viability studies were performed to investigate a possible cytotoxic effect of the 
formulations on each HEK-293 and Caco-2 cells. The cells were incubated with different 
concentrations of the formulations chosen for the transfection studies. The incubation time 
was set to 4.5 h in accordance with the transfection protocol. The cell viability was then 
quantified with a MTT assay. As shown in Figure 4, a concentration dependent cytotoxicity 
was observed. While the lowest concentration did not show any cytotoxic effect at all, the 
higher concentrations affected the cells. A cell viability of approximately 75% was measured 
after treatment with the highest concentration. For control reasons, also the formulations 
with Lipofectamine® 2000 and the phosphatase inhibitor cocktail were investigated in the 
concentration chosen for further investigations, showing no cytotoxic effect. 
3.5. Enzymatic phosphate cleavage on HEK-293 & Caco-2 monolayers 
The time dependent release of phosphate from the nanoparticles after enzymatic cleavage by 
HEK-293 and Caco-2 monolayers, respectively, was evaluated and results are shown in Figure 
5. On both cell lines, released phosphate could be determined. However, for Caco-2 cells a 
higher amount of cleaved phosphate was measured than for HEK-293 cells. In both cases, the 
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extent of released phosphate was slightly higher for the formulation #4 compared to #1. The 
phosphate-cleavage was significantly reduced in the presence of the phosphatase inhibitor. 
As illustrated in Figure 6, the enzyme alkaline phosphatase could be determined in both tested 
cell lines. Due to the fluorescence in pictures A and the absence of fluorescence  in pictures B, 
a successful binding of the primary antibody to the enzyme and a subsequent binding of the 
fluorescent secondary antibody and thus the presence of alkaline phosphatase was proven. 
3.6. Transfection studies 
GFP assays were performed to verify successful transfection of each HEK-293 and Caco-2 cells 
with nanoparticle formulations #1 and #4, respectively. To investigate the influence of the ζ-
potential change induced by enzymatic phosphate cleavage on the transfection efficiency the 
samples were applied to the cells without and with phosphatase inhibitor. As shown in, Figure 
7, a significantly increased transfection efficiency for both formulations compared to naked 
pDNA could be observed in both cell lines. Furthermore, the transfection efficiency was 
comparable or higher (formulation #4) than that of the pDNA-Lipofectamine® 2000 complex, 
which was applied as control. In contrast, when applied in presence of the phosphatase 
inhibitor, the transfection efficiency was in the same range as the naked pDNA. With HEK-293 
cells, the absolute transfection efficiencies are higher and the differences between the 
samples and the controls are more pronounced than with the Caco-2 cells. 
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4. Discussion 
The CFTR gene therapy is a promising strategy for the treatment of cystic fibrosis as it could 
provide causal treatment independent of the mutation and thus be applicable for a large 
number of patients [14]. However, as with all gene drugs, this demands for an efficient gene 
delivery system because several biological barriers have to be overcome. This system should 
protect the gene from enzymatic degradation, deliver it to the epithelia by crossing the mucus 
gel layer and increase the cellular uptake. In order to fulfill these requirements the 
combination of contrary properties is needed, as for an efficient diffusion through the mucus 
gel layer negatively charged particles are advantageous [6], while cellular uptake is increased 
by positively charged particles [4]. In recent studies, nanoparticles were developed, that are 
capable of changing their ζ-potential in a controlled manner after enzymatic cleavage by brush 
border enzymes [7-10]. -In the present study, this strategy was used to develop a 
nanoparticulate CFTR gene delivery system and evaluate the improvement of transfection 
efficiency caused by the ζ potential change. 
Therefore, two different polymers were modified with phosphotyrosine as functional group 
as described before by our group [7]. Chitosan and carboxymethyl cellulose were each 
conjugated with PTyr in EDAC mediated reactions forming covalent bonds between the amino 
group and the carboxyl group of the respective substrates (Figure 1). PTyr was chosen, as it is 
substrate for the membrane-bound enzyme alkaline phosphatase. The nanoparticles were 
prepared via ionic gelation. Two different types of nanoparticles were prepared in different 
formulations. Type 1 consisted of CS-PTyr and pDNA, in which the negatively charged pDNA 
worked as the counter ion for the positive amino groups of the chitosan. Type 2 contained the 
pDNA and both polymers CS-PTyr and CMC-PTyr, in which both, pDNA and CMC-PTyr worked 
as counter ion. Formulations with different ratios were prepared (Table 1) and for the resulting 
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nanoparticles, ζ potentials between -7 and -17 mV could be determined (Figure 2). Thus, all 
four formulations exhibited the required negative ζ potential. In the next step, the change of 
ζ potential after incubation with intestinal alkaline phosphatase (IAP) was evaluated. The 
enzyme hydrolyses the phosphate ester and the remaining tyrosine is neutral compared to 
the negatively charged phosphotyrosine. This results in a reduced amount of negatively 
charged groups displayed by the nanoparticles and the ratio between positive and negative 
groups displayed by the nanoparticles shifts towards the positive ones, resulting in a ζ 
potential shift. A shift of ζ potential could be observed for all formulations, and a change to 
positive ζ potential was detected for formulations #1 and #4. The difference between the ζ 
potential before and after enzymatic cleavage was higher for formulation #4 consisting of both 
CS-PTyr and CMC-PTyr as more PTyr groups are available for cleavage in this formulation. 
According to these results, formulations #1 and #4 were chosen for further investigations. 
 The chosen nanoparticle formulations were tested for their encapsulation efficiency. 
Encapsulation of the pDNA was higher in formulation #4 than in formulation #1, as in case of 
the latter some pDNA was released into the gel. This indicates that the ionic gelation was more 
effective in presence of CMC-PTyr with its carboxyl group and the pDNA is entrapped by the 
polymers during the nanoparticle formation. This is in accordance with other reports that 
ternary polymeric nanoparticles show improved properties regarding DNA encapsulation and 
gene delivery compared to binary complexes [19-21]. Furthermore, the incomplete 
encapsulation of formulation #1 could explain the increasing negative ζ potential with 
increasing DNA concentrations as observed for formulations #1, #2 and #3.  
While both polymers are well-known for their low toxicity and classified as safe substances by 
the FDA, cytotoxicity studies were performed to evaluate the cytotoxic profile of the 
nanoparticles and investigate suitable nanoparticle concentrations for the upcoming studies 
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employing HEK-293 and Caco-2 cells. A slight concentration dependent toxicity was detected 
and hence the lowest concentrations corresponding to 5 µg pDNA/mL were chosen for further 
investigations, as they showed no decrease in cell viability at all.  
For a successful transfection, the change of ζ potential is the crucial factor as positively 
charged particles enhance the cellular uptake [4]. In case of the prepared nanoparticles, this ζ 
potential change is achieved by the enzymatic hydrolysis of the phosphate group of the 
phosphotyrosine and thus this enzymatic cleavage is the essential requirement for 
transfection studies. Consequently, the enzymatic phosphate cleavage by HEK-293 and Caco-2 
monolayers was evaluated. Both cell lines are reported to produce phosphatase [22,23]. The 
presence of the enzyme in both cell lines could be confirmed by immunocytochemistry. While 
a phosphate release was detected with both cell lines, the amount of released phosphate was 
higher when incubated on Caco-2 cells, which is most likely due to the lower activity of alkaline 
phosphatase in HEK-293 cells [23]. To assess the impact of the enzymatic cleavage and thus 
the ζ potential change, the phosphate elimination was also evaluated in presence of 
phosphatase inhibitor. When the inhibitor was applied, the phosphate release was 
significantly inhibited. A complete suppression could not be achieved in the applied 
recommended concentration, which is in accordance with the information of the supplier, that 
a complete suppression is not possible with one inhibitor cocktail due to different isoforms 
[24]. On the other hand, a higher concentration of inhibitor might cause cytotoxic effects.  
The cellular uptake of the nanoparticles was investigated by transfection studies with both, 
HEK-293 and Caco-2 cells. The CFTR gene was subcloned on a vector that also contains a gene 
encoding for green fluorescence protein (GFP). The expression of the GFP by the cells after 
incubation with the nanoparticles was analyzed to evaluate the transfection efficiency. Cells 
were transfected by both investigated formulations, while for formulation #4, containing both 
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CS-PTyr and CMC-PTyr, higher transfection rates were detected than for formulation #1. 
Transfection efficiencies were significantly higher than that of naked pDNA and comparable 
to the pDNA-Lipofectamine® 2000 complex. Transfection rates and differences were higher 
for HEK-293 cells compared to Caco-2 cells. HEK-293 cells are generally regarded to be easier 
transfected, which also explains why transfection of HEK-293 cells is higher despite the lower 
activity of alkaline phosphatase. Generally, the transfection efficacy of the 
pDNA-Lipofectamine® 2000 complex was in this study comparatively low, as in most other 
studies Lipofectamine® 2000 leads to log-fold improvements. Detailed dose response studies, 
however, were not subject of this investigation. 
The higher transfection of formulation #4 compared to formulation #2 reflect the different 
encapsulation efficiencies and again supports the findings about enhanced gene delivery 
capabilities of ternary compared to binary nanoparticle formulations [19]. Furthermore, these 
results are in accordance with the determination that the ζ potential of formulation #4 after 
enzymatic cleavage was higher than that of formulation #1, and thus facilitating cell uptake. 
Electrostatic interactions between the negatively charged cell membrane and positively 
charged particles promote the cell-uptake and higher charge leads to increased cell-uptake 
[3].  In contrast, inhibition of the enzymatic cleavage and hence prevention of ζ potential 
change effected a significantly decreased transfection efficiency which was in the range of 
naked pDNA. Consequently, the ζ potential change is decisive for an effective cellular uptake 
of the developed nanoparticles.  
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5. Conclusion 
This is, to our knowledge, the first time, that pDNA with a cystic fibrosis transmembrane 
conductance regulator gene was incorporated in ζ potential changing nanoparticles. A change 
of ζ potential from negative to positive, induced by enzymatic cleavage of the 
phosphotyrosine, was detected. The pDNA was successfully encapsulated and a successful 
transfection of HEK-293 and Caco-2 cells, with a transfection efficiency in the range of 
Lipofectamine 2000, was shown. According to these findings, the developed nanoparticles 
seem to be a promising gene delivery system. 
  
22 
 
Summary points 
 Phosphotyrosine was conjugated to chitosan and carboxymethyl cellulose, 
respectively. 
  pDNA containing a cystic fibrosis transmembrane conductance regulator gene was 
successfully incorporated into nanoparticles. 
 The ζ potential of the nanoparticles changed from negative to positive after enzymatic 
cleavage by phosphatase. 
 The conjugated phosphotyrosine is enzymatically cleaved by HEK-293 and Caco-2 
monolayers. 
 The encapsulated pDNA was protected against enzymatic degradation by DNase I. 
 HEK-293 and Caco-2 cells were successfully transfected. 
 Transfection efficiency was comparable to that of the pDNA-Lipofectamine® 2000 
complex and significantly higher compared to naked pDNA. 
 Change of ζ potential was decisive for effective cellular uptake. 
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Figures 
Figure 1. 
 
Scheme of synthesis and nanoparticle formulation: Phosphotyrosine (PTyr) was conjugated 
with each chitosan (CS) and carboxymethyl cellulose (CMC) in EDAC mediated reactions. 
Nanoparticles were prepared by ionic gelation of CS-PTyr with pDNA (A) or CS-PTyr with both 
CMC-Ptyr and pDNA (B), respectively. 
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Figure 2. 
 
Change of ζ potential: ζ potential of different nanoparticle formulations before (gray bars) and 
after (white bars) enzymatic cleavage by IAP.  Indicated values are the means of three 
independent experiments ± standard deviation. The ζ potentials of each formulation before 
and after enzymatic cleavage differed significantly (p < 0.001). 
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Figure 3. 
Encapuslation efficiency: agarose gel electrophoresis showing encapsulation of pDNA in 
formulation #1 (A) and formulation #4 (B). Naked pDNA (C) served as control. Gel was 
prestained with Midori Green Advance® and detected under UV light. 
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Figure 4. 
 
Cytotoxicity studies: Influence of formulations #1 and #4, naked pDNA and controls on cell 
viability of HEK-293 (A) and Caco-2 (B) cells by means of MTT assay after incubation of 4.5 h 
with corresponding final pDNA concentrations of 5 (black bars), 10 (gray bars) and 20 (white 
bars) µg/mL.  Indicated values are the means of at least three independent experiments ± 
standard deviation. Significant differences are indicated by *p < 0.05; ***p < 0.001. 
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Figure 5. 
 
Time dependent phosphate release: Graph shows phosphate release from formulations #1 (●) 
and #4 (▲) and the controls with the addition of phosphatase inhibitor cocktail (#1 ○ / #4 Δ) 
after incubation on HEK-293 (A) and Caco-2 (B) cells. Indicated values are the means of at least 
three experiments ± standard deviation. Indicated values are the means of at least three 
independent experiments ± standard deviation. 
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Figure 6. 
 
Immunocytochemistry images: stained alkaline phosphatase in HEK-293 cells (A: positive 
control and B: negative control) and in Caco-2 cells (C: positive control and D: negative 
control). 
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Figure 7. 
 
Transfection efficiency of formulations #1 and #4 and controls in HEK-293 (A) and Caco-2 (B) 
cells depicted as fluorescence intensity of GFP. The experiment was also carried out in the 
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presence of a phosphatase inhibitor as control. Indicated values are the means of at least 
three independent experiments ± standard deviation. Significant differences are indicated as 
*p < 0.05; **p < 0.01; ***p < 0.001. Fluorescence intensity of formulation #1, formulation #4 
and Lipofectamine 2000 differed significantly from pDNA. Each formulation differed 
significantly from the controls with phosphate inhibitor. 
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Table 1.
Composition of different nanoparticle formulations. 
Formulation 
 
Amount CS-PTyr 
(µg/mL) 
Amount pDNA  
(µg/mL) 
Amount CMC-PTyr 
(µg/mL) 
#1 100 65 - 
#2 100 75 - 
#3 100 85 - 
#4 100 65 200 
 
CMC: Carboxymethyl cellulose; CS: Chitosan; CS-PTyr: Phosphotyrosine-bearing CS derivative; 
CMC-PTyr: Phosphotyrosine-bearing CMC derivative; PTyr: Phosphotyrosine. 
 
